Tumor-derived circulating endothelial cells as a biomarker in locally advanced and metastatic clear cell renal cell carcinoma
Recruiting
- Conditions
- Clear cell renal cell carcinoma, endothelial cell, metastatic disease, VEGFR-TKI
- Registration Number
- NL-OMON25402
- Lead Sponsor
- Erasmus MC Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 75
Inclusion Criteria
Patients with locally advanced or metastatic clear cell renal cell carcinoma
- Candidate for receiving first-line therapy with sunitinib or pazopanib
Exclusion Criteria
- Serious illness or medical unstable condition prohibiting adequate treatment and follow-up
- Previous treatment with systemic therapy for clear cell renal cell carcinoma
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The value of CD276-positive CECs in locally advanced or metastatic clear cell renal cell caricnoma before start VEGFR-TKI based therapy
- Secondary Outcome Measures
Name Time Method - The association of CD276-positive CEC count in locally advanced or metastatic clear cell renal cell carcinoma with PFS at 12 months<br /><br>- The association of changes after 4 weeks of VEGFR-TKI treatment in CD276-positive CEC count in locally advanced or metastatic clear cell renal cell carcinoma with PFS at 12 months